Researchers in Japan are exploring a future where the body itself becomes a health monitor, no screens or batteries required.

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Each immune cell group has distinct metabolic requirements, activation pathways, and cytokine reliance. Standard, one-size-fits-all media cannot address these features. When studying diverse cell ...

Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presentedDosing of the final cohort in the first in human study has ...

Inflammation has to fight pathogens fast—but it can't get out of control. Researchers at the German Cancer Research Center ...

New research published in the peer-reviewed science journal, Immuno, reports that Hericium erinaceus (Lion's Mane) ...

Preclinical data suggest neratinib dampens vascular inflammation and atherosclerosis by targeting ASK1 in endothelial cells, ...

Inflammation hasto fight pathogens fast—but it can't get out of control. Researchers at the German Cancer Research Center (DKFZ) have now deciphered in more detail how the organism masters this ...

Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...

T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalitiesCizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseasesOver 60 ...

Company to Initiate First-in-Human Phase 1 Clinical Trial in Q2 2026ROCKVILLE, Md.--(BUSINESS WIRE)--#Clinicaltrials--Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage ...